Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q3 2026 · 10-Q
Revenue$303.00K$303.00K+29.5% vs Q3 2025 Net Income-$18.90M-$18.90MN/M vs Q3 2025 EPS Diluted-$0.45-$0.45N/M vs Q3 2025 Operating Income-$19,546,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-6450.8%+10.7 pt vs Q3 2025
Net margin-6237.3%−216.4 pt vs Q3 2025
ended Dec 31, 2025 · filed Feb 12, 2026 · 43 d after period end